191602-43-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-4-isopropoxyaniline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties. Its unique structure allows for the creation of molecules with targeted actions and improved pharmacokinetics.
Used in Dye Industry:
In the dye industry, 3-Bromo-4-isopropoxyaniline is used as a precursor for the production of dyes with specific color characteristics and properties. Its chemical structure enables the creation of dyes with enhanced stability and colorfastness, suitable for various applications.
Used in Organic Chemistry Research:
3-Bromo-4-isopropoxyaniline is utilized as a research compound in organic chemistry, where it serves as a building block for the development of novel organic compounds with potential applications in various fields. Its reactivity and functional groups make it a valuable tool for exploring new chemical reactions and syntheses.
Safety Considerations:
Given its classification as a hazardous chemical, 3-Bromo-4-isopropoxyaniline should be handled with care, adhering to proper safety protocols and regulations to minimize risks to human health and the environment.

Upstream product

• 5847-59-6 2-bromo-4-nitrophenol 
• 191602-42-3 2-bromo-1-isopropoxy-4-nitrobenzene 

Downstream Products

• 921194-46-9 4-isopropoxy-3-vinylaniline 

Relevant academic research and scientific papers

BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF

β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.

Activated pyridinium-tagged ruthenium complexes as efficient catalysts for ring-closing metathesis

New pyridinium-tagged ruthenium catalysts have been synthesised to perform olefin metathesis in several media including both organic and aqueous solvents and room temperature ionic liquids (RTILs). High activity was obtained in the ring-closing metathesis (RCM) of a variety of di- or tri-substituted and/or oxygen-containing dienes. However, only fair levels of recycling combined with low to moderate residual ruthenium levels (25-173 ppm) have been observed showing clearly the difficulty of associating high activity and recyclability.

Substituted benzazoles and methods of their use as inhibitors of Raf kinase

New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.